Concepedia

Alba Liliana Gil Gómez

AL

1

Publications

39

Citations

1

H-Index

2010

Active since

Alba Liliana Gil Gómez is an author specializing in cancer therapeutics, health sciences, and surgical oncology.

Top concepts

Publications per year

2010–2010

1

Publications

1

Phase III study of first-line XELOX plus bevacizumab (BEV) for 6 cycles followed by XELOX plus BEV or single-agent (s/a) BEV as maintenance therapy in patients (pts) with metastatic colorectal cancer (mCRC): The MACRO Trial (Spanish Cooperative Group for the Treatment of Digestive Tumors [TTD]).

Josep Tabernero, Enrique Aranda, Alba Liliana Gil Gómez et al. · Journal of Clinical Oncology · 2010 · 39 citations

, , +17

Rows per page

1–1 of 1